Aveo On­col­o­gy gets the long-await­ed green­light to mar­ket tivozanib — 9 years af­ter fil­ing its first NDA

Sev­en years af­ter Aveo On­col­o­gy’s tivozanib was sub­ject­ed to a scathing dress­down by the FDA’s can­cer czar Richard Paz­dur — fol­lowed by a swift re­jec­tion and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER